17HP Ester Oral Compositions for Preterm Birth Support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering 17-hydroxyprogesterone caproate to prevent preterm birth require frequent intramuscular injections, causing patient distress, anxiety, and disruption in daily life, with limited oral bioavailability due to low water solubility and susceptibility to hepatic inactivation, making oral delivery challenging.
Innovation Solution
Development of pharmaceutical oral compositions and dosage forms that incorporate solubilizing agents like benzyl alcohol, enabling effective bioavailability and release of 17HP esters, allowing for higher loading and improved patient compliance through reduced frequency and size of dosage units, and providing effective bioavailability through solid dosage forms such as tablets and particulates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intramuscular injection of 17-hydroxyprogesterone caproate is used to prevent preterm birth, then progestational effect is achieved, but patient distress and disruption in daily life increase due to frequent injections
Solution Approach 1:
The patent replaces the mechanical injection system with an oral pharmaceutical composition system. The composition includes 17-hydroxyprogesterone caproate combined with specific carriers and excipients that enable oral bioavailability, eliminating the need for intramuscular injections while maintaining therapeutic effectiveness for preventing preterm birth.
Solution Approach 2:
The patent changes the administration route parameter from parenteral (injection) to oral. This involves modifying the drug formulation parameters by incorporating solubilizing agents, carriers, and excipients that enable the lipophilic 17-hydroxyprogesterone caproate to be effectively absorbed through the gastrointestinal tract, thereby changing the delivery system from injection-based to oral-based.
2Ease of operation
If oral administration of 17-hydroxyprogesterone caproate is attempted, then patient compliance improves, but bioavailability is limited due to low water solubility and hepatic inactivation
Solution Approach 1:
The patent introduces intermediary substances including solubilizing agents (such as cyclodextrins, phospholipids, or surfactants), carriers, and excipients that facilitate the absorption of 17-hydroxyprogesterone caproate in the gastrointestinal tract. These intermediaries overcome the low water solubility and first-pass metabolism issues, enabling effective oral bioavailability while maintaining patient compliance.
Solution Approach 2:
The patent creates a composite pharmaceutical composition that combines 17-hydroxyprogesterone caproate with multiple functional components including solubilizing agents, carriers, and excipients. This composite formulation synergistically addresses the solubility and bioavailability challenges, allowing effective oral delivery while maintaining therapeutic effectiveness.
3Reliability
If frequent intramuscular injections are administered, then therapeutic effect is maintained, but loss of time and disruption in daily life increase
Solution Approach 1:
The patent enables continuous therapeutic action through oral administration that can be conveniently taken at home, eliminating the need for frequent clinic visits for injections. The formulation is designed to provide sustained progestational effect through regular oral dosing, maintaining therapeutic levels while allowing patients to integrate treatment into their daily routine without significant disruption.
4Ease of operation
If 17-hydroxyprogesterone caproate is formulated for oral delivery, then patient compliance improves, but manufacturing complexity increases due to solubility challenges
Solution Approach 1:
The patent modifies formulation parameters by selecting specific carriers, solubilizing agents, and excipients with proven compatibility and efficacy. These parameter optimizations simplify the manufacturing process while ensuring effective oral delivery, balancing the need for complex formulation science with practical manufacturability and patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oral compositions achieve significant bioavailability and prolonged release of 17HP esters, reducing the frequency of administration, enhancing patient compliance, and overcoming the limitations of intramuscular injections by providing a stable and effective therapeutic effect.
Implementation Method 1
incorporate solubilizing agents like benzyl alcohol, enabling effective bioavailability and release of 17HP esters
Implementation Method 2
Development of pharmaceutical oral compositions and dosage forms that incorporate solubilizing agents like benzyl alcohol, enabling effective bioavailability and release of 17HP esters
Data Source
AI summary
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.